{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:06:43Z","timestamp":1777774003001,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shionogi and Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01327-2","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:23:28Z","timestamp":1775035408000},"page":"1451-1466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD)"],"prefix":"10.1007","volume":"15","author":[{"given":"Mineaki","family":"Kitamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-5386","authenticated-orcid":false,"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-2277","authenticated-orcid":false,"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9666-8678","authenticated-orcid":false,"given":"Ryosuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1498445","volume":"13","author":"DP Maison","year":"2025","unstructured":"Maison DP, Tasissa H, Deitchman A, et al. COVID-19 clinical presentation, management, and epidemiology: a concise compendium. Front Public Health. 2025;13:1498445.","journal-title":"Front Public Health"},{"issue":"1","key":"1327_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9010047","volume":"9","author":"CY Chen","year":"2021","unstructured":"Chen CY, Shao SC, Chen YT, et al. Incidence and clinical impacts of COVID-19 infection in patients with hemodialysis: systematic review and meta-analysis of 396,062 hemodialysis patients. Healthcare. 2021;9(1):47.","journal-title":"Healthcare (Basel)"},{"issue":"9","key":"1327_CR3","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.ekir.2023.06.008","volume":"8","author":"T Takazono","year":"2023","unstructured":"Takazono T, Ngwe Tun MM, Funakoshi S, et al. Long-term neutralizing antibody titers after BNT162b2 vaccination in hemodialysis patients. Kidney Int Rep. 2023;8(9):1883\u20136.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"1327_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01389-9","volume":"28","author":"B Zeng","year":"2023","unstructured":"Zeng B, Zhou J, Peng D, Dong C, Qin Q. The prevention and treatment of COVID-19 in patients treated with hemodialysis. Eur J Med Res. 2023;28(1):410.","journal-title":"Eur J Med Res"},{"issue":"1","key":"1327_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11684-023-1011-0","volume":"18","author":"X Hao","year":"2024","unstructured":"Hao X, Bao Z, Dai R, et al. A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections. Front Med. 2024;18(1):169\u201379.","journal-title":"Front Med"},{"key":"1327_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1161897","volume":"14","author":"J Lu","year":"2023","unstructured":"Lu J, Cai H, Hao Y, et al. Nirmatrelvir\/Ritonavir for hemodialysis patients with COVID-19. Front Pharmacol. 2023;14:1161897.","journal-title":"Front Pharmacol"},{"key":"1327_CR7","unstructured":"U.S. Food and Drug Administration. Paxlovid. Package insert. Pfizer; 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217188s008lbl.pdf. Accessed September 05, 2025."},{"key":"1327_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1053814","volume":"14","author":"A Kale","year":"2023","unstructured":"Kale A, Shelke V, Dagar N, Anders HJ, Gaikwad AB. How to use COVID-19 antiviral drugs in patients with chronic kidney disease. Front Pharmacol. 2023;14:1053814.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1327_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","volume":"60","author":"R Humeniuk","year":"2021","unstructured":"Humeniuk R, Mathias A, Kirby BJ, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor. Clin Pharmacokinet. 2021;60(5):569\u201383.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1327_CR10","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1093\/ckj\/sfac185","volume":"15","author":"KE Zaki","year":"2022","unstructured":"Zaki KE, Huang CW, Zhou H, et al. Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19. Clin Kidney J. 2022;15(11):2056\u201362.","journal-title":"Clin Kidney J"},{"issue":"10","key":"1327_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/v14102224","volume":"14","author":"P Pozna\u0144ski","year":"2022","unstructured":"Pozna\u0144ski P, Augustyniak-Bartosik H, Magiera-\u017bak A, et al. Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients. Viruses. 2022;14(10):2224.","journal-title":"Viruses"},{"issue":"9","key":"1327_CR12","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh Y, Uehara S, Nakahara K, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65(9):6499\u2013512.","journal-title":"J Med Chem"},{"key":"1327_CR13","unstructured":"Shionogi & Co., Ltd. Shionogi announces Xocova\u00ae (Ensitrelvir Fumaric Acid) obtained standard approval in Japan for the treatment of SARS-CoV-2 infection. https:\/\/www.shionogi.com\/global\/en\/news\/2024\/03\/20240305.html. Accessed September 05, 2025."},{"key":"1327_CR14","unstructured":"Shionogi & Co., Ltd. Xocova\u00ae (Ensitrelvir Fumaric Acid) tablets 125mg approved in Japan for the treatment of SARS-CoV-2 infection, under the Emergency Regulatory Approval System. https:\/\/www.shionogi.com\/global\/en\/news\/2022\/11\/e20221122.html. Accessed September 05, 2025."},{"issue":"10","key":"1327_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00697-22","volume":"66","author":"H Mukae","year":"2022","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, et al. A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part. Antimicrob Agents Chemother. 2022;66(10):e0069722.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1327_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54991","volume":"7","author":"H Yotsuyanagi","year":"2024","unstructured":"Yotsuyanagi H, Ohmagari N, Doi Y, et al. Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw Open. 2024;7(2):e2354991.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1327_CR17","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s40262-024-01446-4","volume":"63","author":"T Ishibashi","year":"2024","unstructured":"Ishibashi T, Shimizu R, Kubota R. Population pharmacokinetics of ensitrelvir in healthy participants and participants with SARS-CoV-2 Infection in the SCORPIO-SR study. Clin Pharmacokinet. 2024;63(12):1723\u201334.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1327_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s40121-024-00946-x","volume":"13","author":"T Katsube","year":"2024","unstructured":"Katsube T, Kezbor S, Shimizu R, Kubota R. Effect of renal impairment on pharmacokinetics and safety of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor. Infect Dis Ther. 2024;13(3):597\u2013607.","journal-title":"Infect Dis Ther"},{"key":"1327_CR19","unstructured":"Pharmaceuticals and Medical Devices Agency. Ensitrelvir. Review report; 2024. https:\/\/www.pmda.go.jp\/files\/000273156.pdf. Accessed September 05, 2025."},{"issue":"9","key":"1327_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jiac.2024.02.015","volume":"30","author":"M Yamato","year":"2024","unstructured":"Yamato M, Kinoshita M, Miyazawa S, Seki M, Mizuno T, Sonoyama T. Ensitrelvir in patients with SARS-CoV-2: a retrospective chart review. J Infect Chemother. 2024;30(9):946\u201350.","journal-title":"J Infect Chemother"},{"issue":"10","key":"1327_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40261-023-01309-z","volume":"43","author":"R Shimizu","year":"2023","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations. Clin Drug Investig. 2023;43(10):785\u201397.","journal-title":"Clin Drug Investig"},{"key":"1327_CR22","unstructured":"R Core Team (2023). R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. https:\/\/www.R-project.org\/. Accessed September 05, 2025."},{"issue":"2","key":"1327_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2023.100638","volume":"47","author":"TH Lee","year":"2024","unstructured":"Lee TH, Chen JJ, Wu CY, Lin TY, Hung SC, Yang HY. Immunosenescence, gut dysbiosis, and chronic kidney disease: interplay and implications for clinical management. Biomed J. 2024;47(2):100638.","journal-title":"Biomed J"},{"issue":"1","key":"1327_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10047-018-1059-9","volume":"22","author":"M Kohlov\u00e1","year":"2019","unstructured":"Kohlov\u00e1 M, Amorim CG, Ara\u00fajo A, Santos-Silva A, Solich P, Montenegro M. The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease. J Artif Organs. 2019;22(1):14\u201328.","journal-title":"J Artif Organs"},{"issue":"5","key":"1327_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.kint.2022.01.022","volume":"101","author":"K El Karoui","year":"2022","unstructured":"El Karoui K, De Vriese AS. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney Int. 2022;101(5):883\u201394.","journal-title":"Kidney Int"},{"issue":"8","key":"1327_CR26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/cid\/ciac933","volume":"76","author":"H Mukae","year":"2023","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study. Clin Infect Dis. 2023;76(8):1403\u201311.","journal-title":"Clin Infect Dis"},{"key":"1327_CR27","unstructured":"European Medicines Agency. Paxlovid: EPAR\u2014Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf. Accessed September 30, 2025."},{"issue":"3","key":"1327_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.12.003","volume":"31","author":"N Hayashi","year":"2025","unstructured":"Hayashi N, Tsukimura E, Ogura E. Ensitrelvir for the treatment of COVID-19: final analysis of a post-marketing surveillance from Japan. J Infect Chemother. 2025;31(3):102574.","journal-title":"J Infect Chemother"},{"key":"1327_CR29","volume":"12","author":"H Mukae","year":"2025","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, et al. Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review. Ther Adv Infect Dis. 2025;12:20499361251321724.","journal-title":"Ther Adv Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01327-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01327-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:34:09Z","timestamp":1777484049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01327-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01327-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takahiro Takazono has received personal fees from Shionogi & Co., Ltd., MSD Co., Ltd., Pfizer Inc., Insmed Japan, Asahi Kasei Pharma Corporation, and Kyorin Pharmaceutical Co., Ltd. Naoki Hosigaya has no COI to disclose. Tomoya Nishino, Shimpei Morimoto, Mineaki Kitamura,\u00a0and Hiroshi Mukae received personal fees from Shionogi & Co., Ltd., MSD Co., Ltd., Gilead Science, AstraZeneca K.K., Pfizer Inc., and GSK. Masahiro Kinoshita, Eriko Hamada, Ryosuke Shimizu, Shogo Miyazawa, and Shintaro Tanaka are employees of Shionogi & Co., Ltd. and its subsidiary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The trial was conducted in accordance with the Declaration of Helsinki and Japan\u2019s Clinical Research Act. Ethical approval was obtained from the Nagasaki University Clinical Research Review Committee\u00a0(CRB24-006). Written informed consent was obtained from all patients prior to any study-related procedure, and confidentiality was maintained using unique identifiers and secure EDC systems.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}